-+ 0.00%
-+ 0.00%
-+ 0.00%

Oculis Secures FDA Breakthrough Therapy Designation For Privosegtor In Optic Neuritis As PIONEER Program Targets $7B US Neuroprotective Market

Benzinga·01/06/2026 09:11:02
Listen to the news
  • Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis
  • Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S.
  • Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroid alone at month 3 in the ACUITY trial